Thomson Reuters Launches IDRAC(R) Notes

PHILADELPHIA and LONDON - New Commenting Feature Facilitates Increased Collaboration With
Colleagues

The Healthcare and Science business of Thomson Reuters has launched
IDRAC(R) Notes, an add-on commenting feature to IDRAC. This will allow
colleagues within the same organization to create, update and share comments
attached to IDRAC PDF documents.

Designed from user feedback, IDRAC Notes improves collaboration and
communication on regulatory affairs matters and improves information sharing
and interpretation of regulatory requirements.

“Users rely on IDRAC to keep up with ever-changing regulatory
requirements,” said Claude Basset, VP Specialty Markets at Thomson Reuters.
“With the addition of IDRAC Notes, they now have the ability to capture, edit
and share internal knowledge in a quick, easy and secure process.”

IDRAC, the regulatory intelligence solution of choice for the global
pharmaceutical industry, allows organizations to get products to market
faster and minimize regulatory risk by providing trusted information and
analysis on the most up-to-date regulatory requirements.

For more information on IDRAC, please visit
www.thomsonreuters.com/products_services/scientific/IDRAC.

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information
for businesses and professionals. We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare
and media markets, powered by the world’s most trusted news organization.
With headquarters in New York and major operations in London and Eagan,
Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries.
For more information, go to thomsonreuters.com.

Source: Thomson Reuters

Sue Besaw, Healthcare and Science of Thomson Reuters, +1-215-823-1840, susan.besaw at thomsonreuters.com